Comparative effects on bone mineral density of tibolone, transdermal estrogen and oral estrogen/progestogen therapy in postmenopausal women

References

• Lindasy R., Hart D. M., Aitken J. M., Mac-Donald E. B., Anderson J. B., Clarke A. C. Long-term prevention of postmenopausal osteoporosis by oestrogen. Lancet 1976; 1: 1038–41
   PubMedGoogle Scholar
• Christiansen C., Christensen M. S., Transbol I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestogen replacement therapy. Lancet 1981; 1: 459–61
   PubMed Web of Science ®Google Scholar
• Ettinger B., Genant H. K., Cann C. E. Postmenopausal bone loss is prevented by treatment with low dosage oestrogen with calcium. Ann. Intern. Med. 1987; 106: 40–55
   PubMed Web of Science ®Google Scholar
• Civitelli R., Agnusdci D., Nardi P., Zacchei F., Avioli L. V., Gennari C. Effects of one-year treatment with oestrogens on bone mass, intestinal calcium absorption and 25-hydroxy-vitamin D-1 alpha-hydroxylase reserve in postmenopausal osteoporosis. Calcif. Tissue Int. 1988; 42: 77–86
   PubMed Web of Science ®Google Scholar
• Lindasy R., Tohme J. F. Oestrogen treatment of patients with established postmenopausal osteoporosis. Obstet. Gynaecol. 1990; 76: 290–5
   Web of Science ®Google Scholar
• Felson D. T., Zhang Y., Hannan M. T., Kiel D., Wilson P. W. F., Anderson J. J. The efect of postmenopausal estrogen therapy on bone density in elderly women. N. Engl. J. Med. 1993; 329: 1141–6
   PubMed Web of Science ®Google Scholar
• Lufkin E. G., Warmer H. W., O'Fallon W. M. O., Hodgson S. F., Kotowicz M. A., Lane A. W., Judd H. L., Caplan R. H., Riggs L. B. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann. Int. Med. 1992; 117: 1–9
   PubMed Web of Science ®Google Scholar
• Kanis J. A., Johnell O., Gullberg B., Allander E., Dilsen G., Gennari C., LopezVaz A. A., Lyritis G. P., Mazzuoli G., Miravet L., Passen M., Cano R. P., Rapado A., Ribot C. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fractures. Br. Med. J. 1992; 305: 1124–8
   PubMed Web of Science ®Google Scholar
• Maxim P., Ettinger B., Spitalmy G. M. Fracture protection provided by long-term estrogen treatment. Osteoporosis Int. 1995; 5: 23–9
   PubMed Web of Science ®Google Scholar
• Kicovic P. M., Cortes-Prieto J., Luisi M., Milojevic S., Franchi F. Placebo controlled cross-over study of effects of Org OD 14 in menopausal women. Reproduction 1982; 6: 81–9
   Google Scholar
• Nevinny-Stickel J. Double-blind crossover study with Org OD 14 and placebo in postmenopausal patients. Arch. Gynaecol. 1983; 234: 27–31
   PubMedGoogle Scholar
• Ginsburg J., Prelevic G., Butler D., Okolo S. Clinical experience with tibolone (Livial(r)) over eight years. Maturitas 1995; 21: 71–6
   PubMed Web of Science ®Google Scholar
• Lindsay R., McKayHart D., Kraszewski A. Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. Br. Med. J. 1980; 1: 1207–9
   Google Scholar
• Fogelman I., Bessent R. G., Smith M. L., Hart D. M., Lindsay R. Assessment of synthetic steroid (Org OD 14): effect on skeletal metabolism by 24 h whole-body retention of diphosphonate. Maturitas 1981; 3: 266–9
   Web of Science ®Google Scholar
• Guesens P., Dequeker J., Gielen J., Schot L. P. C. Non-linear increase in vertebral density induced by a synthetic steroid (Org OD 14) in women with established osteoporosis. Maturitas 1991; 13: 155–62
   PubMed Web of Science ®Google Scholar
• Rymer J., Chapman M., Fogelman I. Effect of tibolone on postmenopausal bone loss. Osteoporosis Int. 1994; 4: 314–19
   PubMed Web of Science ®Google Scholar
• Lyritis G. P., Karpathuios S., Basdekis K., Grigoriou O., Katostratas T., Paspati I., Stama-Topoulos T., Siampalioti G., Lyritis P. G. Prevention of post-oophorectomy bone loss with tibolone. Maturitas 1995; 22: 247–53
   PubMed Web of Science ®Google Scholar
• Lindsay C. P., Shaw R. W., CoelinghBennink H. J.T., Kicovic P. M. The effect of add-back treatment with tibolone (Livial) on patients treated with gonadotrophin-releasing hormone agonist triptorelin (Decapeptyl). Fertil. Steril. 1996; 65: 342–8
   PubMed Web of Science ®Google Scholar
• Pavlov P. W., Ginsburg J., Kicovic P. M., Van derSchaaf D. B., Prelevic G., Coelingh Bennink H. J. T. Double-blind, placebo-controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures. Osteoporosis Int. 1996, in press
   Google Scholar
• Selby P. L., Peacock M. Dose-dependent response of symptoms, pituitary and bone to transdermal oestrogen in postmenopausal women. Br. Med. J. 1986; 293: 1337–9
   PubMed Web of Science ®Google Scholar
• Studd J. W. W., Savvas M., Watson N., Garnett T., Fogelman I., Cooper D. The relationship between plasma estradiol and the increase in bone density in postmenopausal women after treatment with subcutaneous hormone implants. Am. J. Obstet. Gynecol. 1990; 163: 1474–9
   PubMed Web of Science ®Google Scholar
• Lindsay R., Hart D. M., Purdie D., Ferguson M. M., Clark A. S., Kraszewski A. Comparative effects of oestrogen and a progestogen on bone loss in postmenopausal women. Clin. Sci. Mol. Med. 1978; 54: 193–5
   PubMedGoogle Scholar
• Horowitz M., Wishart J. M., Need A. G., Morns H. A., Nordin C. B. E. Effects of norethisterone on bone related biochemical variables and forearm bone mineral in postmenopausal osteoporosis. Clin. Endocrinol. 1993; 39: 649–55
   PubMed Web of Science ®Google Scholar
• Grey A., Cundy T., Evans M., Reid I. Medroxyprogesterone acetate enhances the spinal bone mineral density response to oestrogen in late postmenopausal women. Clin. Endocrinol. 1996; 44: 293–6
   PubMed Web of Science ®Google Scholar
• Evans S. F., Davie M. W. Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all post-mcnopausal ages. Clin. Endocrinol. 1996; 44: 79–84
   PubMed Web of Science ®Google Scholar
• Watts N. B., Harris S. T., Genant H. K., Wasnich R. D., Miller P. D., Jackson R. D. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N. Engl. J. Med. 1990; 323: 723–9
   Web of Science ®Google Scholar
• Storm T., Thamsborg G., Steiniche T., Genant H. K., Sorensen O. H. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N. Engl. J. Med. 1990; 322: 1265–71
   PubMed Web of Science ®Google Scholar
• Overgaard K., Hansen M. A., Jensen S. B., Christiansen C. Effect of salcalcitonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. Br. Med., J. 1992; 305: 556–61
   PubMed Web of Science ®Google Scholar